Side-by-side · Research reference

LiraglutidevsSelank

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedVerified14/45 cited

BHuman-MechanisticDraft11/40 cited

Liraglutide

Daily GLP-1 RA · FDA-Approved

0.6–3.0 mgDaily doseSAXENDA (liraglutide) injectio 2014

5–10%Body-weight ↓SAXENDA (liraglutide) injectio 2014

~13 hrHalf-lifeSAXENDA (liraglutide) injectio 2014

SQ · Abdomen / thigh / arm · Once daily

Selank

Anxiolytic + Cognitive · Russian Pharma

150–300 mcg/doseIntranasalZaderej 2014

HumanMechanisticZaderej 2014 Medvedev 2007

~30 minOnset

Intranasal · 2–3×/day during stress / cognitive demand

01Mechanism of Action

Parameter

Liraglutide

Selank

Primary target

GLP-1 receptor (GLP-1R)SAXENDA (liraglutide) injectio 2014

Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014

Pathway

GLP-1R agonism → ↑glucose-dependent insulin, ↓glucagon, ↓gastric emptying, ↓appetiteSAXENDA (liraglutide) injectio 2014 Marso 2016

Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007

Downstream effect

Glycemic improvement, modest body-weight reduction, cardiovascular event reduction in high-risk T2DMarso 2016

Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007 Zaderej 2014

Feedback intact?

Glucose-dependent insulin release preserves physiological feedback

No GABA-receptor binding; no dependence reportedMedvedev 2007

Origin

Modified GLP-1(7-37) with Lys26 substitution (Arg34) and C-16 palmitoyl-glutamate acylation for albumin bindingSAXENDA (liraglutide) injectio 2014

Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014

Antibody development

—

02Dosage Protocols

Parameter

Liraglutide

Selank

Standard dose (T2D, Victoza)

1.2–1.8 mg / daySAXENDA (liraglutide) injectio 2014

—

Standard dose (weight, Saxenda)

3.0 mg / day (after 5-week titration)SAXENDA (liraglutide) injectio 2014

—

Frequency

Once daily, same time each day

2–3× per day during stress

Titration schedule

0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks

Mitigates GI side effects.

—

Evidence basis

FDA-approved · Phase 3 RCTs (LEADER, SCALE)Marso 2016 SAXENDA (liraglutide) injectio 2014

Human-mechanistic + Russian clinical trialsMedvedev 2007

Duration

Indefinite for chronic indication

10–14 day cycles, repeated as needed

Reconstitution

Pre-filled commercial pen (no reconstitution)

Pre-formulated nasal spray (commercial); research vial: bacteriostatic water

Timing

Any time of day; consistent

Morning + early afternoon preferred

Half-life

~13 hrSAXENDA (liraglutide) injectio 2014

Short (minutes plasma); CNS effect lasts ~3 hr

Standard dose

—

150–300 mcg / dose intranasalZaderej 2014

Lower / starter dose

—

75 mcg / dose

04Side Effects & Safety

Parameter

Liraglutide

Selank

GI symptoms

Nausea, vomiting, diarrhea (very common during titration)SAXENDA (liraglutide) injectio 2014

—

Pancreatitis risk

Rare; discontinue if suspected

—

Thyroid C-cell tumours

Boxed warning — contraindicated in MEN2 / MTC historySAXENDA (liraglutide) injectio 2014

—

Hypoglycemia

Low risk as monotherapy; elevated with sulfonylureas / insulin

—

Heart rate

Modest ↑ resting HR (~2-3 bpm)

—

Cardiovascular benefit

↓ MACE in high-risk T2D (LEADER trial)Marso 2016

—

Pregnancy / OB

Contraindicated

Avoid — insufficient data

Nasal irritation

—

Mild burning or congestion (transient)

Sedation

—

None — distinct from benzodiazepinesMedvedev 2007

Dependence / withdrawal

—

None reported in clinical useZaderej 2014

Cognitive impairment

—

None — opposite effect (enhancement)

Allergic reaction

—

Rare hypersensitivity

Long-term safety

—

Limited Western RCT data

Absolute Contraindications

Liraglutide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to liraglutide

Selank

·Pregnancy / breastfeeding
·Hypersensitivity to peptide

Relative Contraindications

Liraglutide

·Severe gastroparesis
·History of pancreatitis
·Severe gastrointestinal disease

Selank

·Active autoimmune disease (theoretical via immunomodulation)

05Administration Protocol

Parameter

Liraglutide

Selank

1. Reconstitution / device

Commercial pre-filled pen, no reconstitution required.

Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.

2. Injection site

SQ — abdomen, thigh, or upper arm. Rotate sites.

Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.

3. Timing

Once daily, same time each day. Take with or without food.

Morning + early afternoon for cognitive demand; PRN for acute anxiety.

4. Storage

Refrigerate 2–8 °C unopened; room temp ≤30 °C up to 30 days after first use.

Refrigerate after reconstitution; ≤30 days. Light-protected.

5. Needle

Pen-supplied 32G needle.

Avoid co-administration with strong sedatives or other anxiolytics initially.